were associated with debilitating side effects, and, generally, were contraindicated in patients with decompensated cirrhosis or, in the case of ribavirin, advanced chronic kidney disease (CKD). 7, 8 DAAs reduce morbidity and result in sustained virological response 12 weeks after completing treatment (SVR12) rates >94% for most genotypes in both compensated and decompensated patients. 4, 9, 10 DAAs have also been safely used in the post LT setting to prevent recurrent inflammation and fibrosis, which was universal in the absence of effective pretransplant treatment. Historically, recurrence of HCV in the liver graft resulted in cirrhosis in 20%-30% of LT recipients and fibrosing cholestatic hepatitis C in 2%-9% within the first 12 months. 11, 12 DAAs have been shown to achieve SVR12 after LT in multiple clinical trials, although the impact of DAAs on longer-term LT and KT outcomes has not been reported. 12 Among patients with end-stage renal disease (ESRD), HCV prevalence is 5 times greater than in the general population. 13, 14 Historically, HCV-infected ESRD patients on dialysis were 60% more likely to die than their noninfected counterparts. Prior to DAAs, interferon-based regimens had low levels of efficacy and high rates of intolerability in this population and were generally contraindicated in HCV-infected KT recipients because of unacceptable rates of rejection and allograft dysfunction. Because most HCV-infected KT recipients in the pre-DAA era were therefore either untreated or intolerant to pretransplant interferon/ribavirin, these patients experienced higher rates of graft loss and death than noninfected patients. 15 In contrast, DAAs are both safe and well tolerated in patients with advanced CKD, with SVR12 rates from 95% to 98%. 16, 17 DAA treatment in KT recipients successfully eradicates the virus without negatively affecting graft function in clinical series. 18, 19 While DAA treatment is revolutionary, access to it has been hampered nationally by its high cost. [20] [21] [22] Initial regimens resulted in total healthcare expenditures exceeding $100 000 USD (United 
| HCV treatments
Using pharmacy fill records, we identified claims for approved HCV medications and combinations. In the pre-DAA era, defined as before January 2014, HCV treatment was defined as pegylated interferon, interferon, and ribavirin. DAA-era HCV treatments, with or without ribavirin, are shown in Table S1 . 
| Analyses

| Demographic characteristics
Donor and recipient characteristics were drawn from the SRTR data.
Pre-and post-DAA-era differences were assessed using Student t test and χ 2 analyses as appropriate.
| Propensity to receive HCV treatment
Kaplan-Meier survival analysis was performed to identify the proportion of patients receiving HCV treatment by era and primary payer. Multivariate regression analyses were separately performed for LT and KT recipients to assess factors correlated with HCV treatment before and after introduction of DAAs. Donor and recipient characteristics, including primary payer, were included as independent variables.
| Cost of treatment analysis
The direct cost of HCV treatment was calculated using pharmacy claims for LT and KT recipients before and after introduction of DAAs.
| Survival analysis
Posttransplant survival was assessed in HCV+ patients who did and did not receive HCV treatment in the pre-and post-DAA eras. Multivariate
Cox proportional hazard models were constructed with HCV treatment as a time-varying covariate. Models were separately constructed for patients noted to be HCV+ on the TRR and for HCV+ patients who received HCV+ donor organs. Donor and recipient characteristics were included as covariates in the model.
| Statistical significance
For all models, P < .05 was used to determine statistical significance.
Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
| Approval
This project was reviewed and approved by the Institutional Review
Board of Saint Louis University.
| RE SULTS
Between 2007 and 2016, 58 509 LTs were performed; pharmacy claims data for at least 1 year after transplant were available for 41 690 (71%) of these (Table 1 ). Among patients with claims, 15 671 (38%) were HCV donor negative and recipient positive (D-/R+), 1468 (3.5%) were D+/R+, and 47 (0.1%) were recorded as D+/R-. In the same period, 157 873 KTs were performed; pharmacy claims data were available for 121 800 (71%). In this population, 3681 (3.0%)
were D-/R+, 1738 (1.4%) were D+/R+, and 294 (0.2%) were D+/R-. (Table S2A ).
| Use of HCV treatment
The impact of payer on LT recipient access differed by DAA era. As expected, HCV treatment was substantially less common in KT recipients; overall, 1.4% received HCV treatments within 3 years of transplant. Utilization was highest, at 22.8%, for D+R+ recipients;
11.3% of D-/R+ recipients received treatment ( Figure 1B 3.71 ). In the post-DAA era, other patients whose race was not black or white and older patients were more likely to be treated (Table S2b) .
| Impact of HCV treatment on patient and graft survival
LT outcomes among all HCV+ recipients have improved in the post-DAA era ( Figure 3A) . Among all HCV+ LT recipients, after adjustment for donor and recipient characteristics, HCV requiring treatment pre-DAA was associated with a significantly higher risk of posttransplant mortality (aHR 1.47 1.68 1.91 , P < .0001) and all-cause graft failure (aHR 1.64 1.85 2.10 , P < .0001) ( Figure 4A ). In contrast, there was not increased risk of death or graft failure post-DAA (aHR for death: 0.74 0.94 1.19 , P = .61; aHR for graft failure: 0.74 0.94 1.19 , P = .62) ( Figure 4 ; Table S3A ). In D-/R+ recipients, HCV treatment pre-DAA was not associated with an increased risk of death (P = .96) or graft failure (P = .40). Among D+/R+ post-DAA, the reduction in the risk of death (aHR 0.34 0.67 1.32 , P = .25) and graft failure (aHR 0.32 0.64 1.26 , P = 0.20) within 3 years of transplant was not statistically significant (Table S3B) .
Among HCV+ KT recipients, there was no significant improvement in unadjusted patient survival post-DAA compared with pre-DAA ( Figure 3B ). In the adjusted analysis, pre-DAA HCV treatment was associated with a non-statistically significant increased risk of death (aHR 0.67 1.80 4.87 , P = .25) and graft failure (aHR 0.71 1.61 3.62 , P = .24) ( Figure 4B ; Table S4A ). There was a nonsignificant (Table S3; Table S4A ). Among D+R+ KT recipients, DAA treatment was associated with nonsignificant reduction in graft failure (aHR 0.27 0.54 1.07 , P = .08) and a statistically significant lower risk of death after KT ( 0.19 0.43 0.95 , P = .04). (Table S4B) 
| Economic analysis
The cost of HCV treatment increased dramatically for LT and KT recipients in the DAA era. The mean direct cost of HCV treatment for D+R+ recipients after LT increased from $9772 USD pre-DAA to $120 096 USD in 2014-2017 (P < .0001). For KT, cost of treatment increased from $4489 USD to $106 747 USD (P < .0001). for HCV-infected kidney candidates, the cost-saving realized by a shorter dialysis burden in these patients must be accounted for as well, especially in regions associated with lengthy waiting times. 35 It is therefore unclear why access to treatment with DAAs should be limited for transplant recipients, who are even more likely to benefit from treatment than dialysis patients. 24, 36 This analysis has several key limitations. First, we lack information regarding viral load and genotype in both the pre-and posttransplant setting. Therefore, it is impossible to determine definitively which patients were actively infected at the time of transplant. This is par- 
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